CCG-63802

CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gαo interaction, with an IC50 value of 1.9 μM[1].

Product Specifications

CAS Number

[620112-78-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

RGS Protein

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ccg-63802.html

Purity

98.83

Solubility

DMSO : 1.67 mg/mL (ultrasonic; warming)

Smiles

N#C/C(C1=NC2=CC=CC=C2S1)=C\C3=C(N=C4C(C)=CC=CN4C3=O)OC5=CC=CC(C)=C5

Molecular Formula

C26H18N4O2S

Molecular Weight

450.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Levi L Blazer, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010 Sep;78 (3) :524-33.|[2]Marina Dobrivojević, et al. Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells. Am J Physiol Cell Physiol. 2012 Dec 15;303 (12) :C1260-8.|[3]Xia Meng, et al. PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. Inflammation. 2018 Dec;41 (6) :2079-2089.